CN1331299A - 一种新的多肽——人dna依赖的rna多聚酶ac40亚单位抑制物9.13和编码这种多肽的多核苷酸 - Google Patents

一种新的多肽——人dna依赖的rna多聚酶ac40亚单位抑制物9.13和编码这种多肽的多核苷酸 Download PDF

Info

Publication number: CN1331299A
Authority: CN; China
Prior art keywords: polynucleotide; polypeptide; rna polymerase; dna; sequence
Prior art date: 2000-06-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN 00116959

Other languages

English (en)

Chinese (zh)

Inventor

毛裕民

谢毅

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Shanghai Biowindow Gene Development Inc

Original Assignee

Shanghai Biowindow Gene Development Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-30

Filing date

2000-06-30

Publication date

2002-01-16

2000-06-30 Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc

2000-06-30 Priority to CN 00116959 priority Critical patent/CN1331299A/zh

2001-06-29 Priority to AU2002210323A priority patent/AU2002210323A1/en

2001-06-29 Priority to PCT/CN2001/001084 priority patent/WO2002026969A1/fr

2002-01-16 Publication of CN1331299A publication Critical patent/CN1331299A/zh

Status Pending legal-status Critical Current

Links

102000004163 DNA-directed RNA polymerases Human genes 0.000 title claims abstract description 144
108090000626 DNA-directed RNA polymerases Proteins 0.000 title claims abstract description 144
239000003112 inhibitor Substances 0.000 title claims abstract description 138
108091033319 polynucleotide Proteins 0.000 title claims abstract description 114
239000002157 polynucleotide Substances 0.000 title claims abstract description 114
102000040430 polynucleotide Human genes 0.000 title claims abstract description 114
102100039851 DNA-directed RNA polymerases I and III subunit RPAC1 Human genes 0.000 title abstract description 8
101710112289 DNA-directed RNA polymerases I and III subunit RPAC1 Proteins 0.000 title abstract description 8
230000001419 dependent effect Effects 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 117
229920001184 polypeptide Polymers 0.000 claims abstract description 108
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 107
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
201000010099 disease Diseases 0.000 claims abstract description 36
238000000034 method Methods 0.000 claims description 83
108090000623 proteins and genes Proteins 0.000 claims description 71
239000000523 sample Substances 0.000 claims description 71
238000009396 hybridization Methods 0.000 claims description 37
230000014509 gene expression Effects 0.000 claims description 34
239000012634 fragment Substances 0.000 claims description 32
239000002773 nucleotide Substances 0.000 claims description 31
125000003729 nucleotide group Chemical group 0.000 claims description 31
150000007523 nucleic acids Chemical class 0.000 claims description 24
230000000694 effects Effects 0.000 claims description 22
150000001875 compounds Chemical class 0.000 claims description 21
102000039446 nucleic acids Human genes 0.000 claims description 18
108020004707 nucleic acids Proteins 0.000 claims description 18
239000005557 antagonist Substances 0.000 claims description 17
230000000295 complement effect Effects 0.000 claims description 15
238000001727 in vivo Methods 0.000 claims description 14
239000013604 expression vector Substances 0.000 claims description 13
201000011510 cancer Diseases 0.000 claims description 12
239000013598 vector Substances 0.000 claims description 12
239000013612 plasmid Substances 0.000 claims description 11
239000000556 agonist Substances 0.000 claims description 10
238000006243 chemical reaction Methods 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
241000700605 Viruses Species 0.000 claims description 7
230000003321 amplification Effects 0.000 claims description 6
238000003199 nucleic acid amplification method Methods 0.000 claims description 6
230000000692 anti-sense effect Effects 0.000 claims description 5
238000003745 diagnosis Methods 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 3
208000026278 immune system disease Diseases 0.000 claims description 3
238000002493 microarray Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
208000031886 HIV Infections Diseases 0.000 claims description 2
208000037357 HIV infectious disease Diseases 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims description 2
230000008485 antagonism Effects 0.000 claims description 2
238000013459 approach Methods 0.000 claims description 2
208000022602 disease susceptibility Diseases 0.000 claims description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
238000004088 simulation Methods 0.000 claims description 2
239000003981 vehicle Substances 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 6
206010028980 Neoplasm Diseases 0.000 abstract description 19
230000009471 action Effects 0.000 abstract description 11
238000004519 manufacturing process Methods 0.000 abstract description 11
OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 abstract 1
238000012270 DNA recombination Methods 0.000 abstract 1
208000031320 Teratogenesis Diseases 0.000 abstract 1
230000013020 embryo development Effects 0.000 abstract 1
108700032141 ganirelix Proteins 0.000 abstract 1
108020004414 DNA Proteins 0.000 description 165
210000004027 cell Anatomy 0.000 description 70
150000001413 amino acids Chemical group 0.000 description 41
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
239000002299 complementary DNA Substances 0.000 description 31
102000004169 proteins and genes Human genes 0.000 description 31
238000005516 engineering process Methods 0.000 description 29
235000018102 proteins Nutrition 0.000 description 29
210000001519 tissue Anatomy 0.000 description 26
108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
229940024606 amino acid Drugs 0.000 description 21
235000001014 amino acid Nutrition 0.000 description 21
239000000047 product Substances 0.000 description 20
108091028043 Nucleic acid sequence Proteins 0.000 description 19
230000008859 change Effects 0.000 description 18
208000032170 Congenital Abnormalities Diseases 0.000 description 14
206010061619 Deformity Diseases 0.000 description 14
108091034117 Oligonucleotide Proteins 0.000 description 14
230000012010 growth Effects 0.000 description 14
238000003752 polymerase chain reaction Methods 0.000 description 14
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
108020004999 messenger RNA Proteins 0.000 description 11
238000001556 precipitation Methods 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
230000006870 function Effects 0.000 description 10
235000013372 meat Nutrition 0.000 description 10
239000000203 mixture Substances 0.000 description 10
241000894006 Bacteria Species 0.000 description 9
206010005003 Bladder cancer Diseases 0.000 description 9
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 9
230000000505 pernicious effect Effects 0.000 description 9
238000000926 separation method Methods 0.000 description 9
238000012360 testing method Methods 0.000 description 9
201000005112 urinary bladder cancer Diseases 0.000 description 9
238000005406 washing Methods 0.000 description 9
230000002159 abnormal effect Effects 0.000 description 8
230000008034 disappearance Effects 0.000 description 8
210000003414 extremity Anatomy 0.000 description 8
238000012216 screening Methods 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000001228 spectrum Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000012528 membrane Substances 0.000 description 7
125000000539 amino acid group Chemical group 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000008827 biological function Effects 0.000 description 6
210000000988 bone and bone Anatomy 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
239000000463 material Substances 0.000 description 6
230000008521 reorganization Effects 0.000 description 6
230000033228 biological regulation Effects 0.000 description 5
230000002759 chromosomal effect Effects 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
210000001672 ovary Anatomy 0.000 description 5
230000008569 process Effects 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
108091092562 ribozyme Proteins 0.000 description 5
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
206010010356 Congenital anomaly Diseases 0.000 description 4
238000000018 DNA microarray Methods 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
238000000636 Northern blotting Methods 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
208000022329 Protein metabolism disease Diseases 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000001035 drying Methods 0.000 description 4
230000008175 fetal development Effects 0.000 description 4
210000004907 gland Anatomy 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000007901 in situ hybridization Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
231100000241 scar Toxicity 0.000 description 4
239000000126 substance Substances 0.000 description 4
210000001550 testis Anatomy 0.000 description 4
210000001541 thymus gland Anatomy 0.000 description 4
210000003932 urinary bladder Anatomy 0.000 description 4
238000002965 ELISA Methods 0.000 description 3
241000206602 Eukaryota Species 0.000 description 3
206010016717 Fistula Diseases 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
206010027336 Menstruation delayed Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
108020005091 Replication Origin Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
238000013016 damping Methods 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
230000003890 fistula Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
201000004637 gastric cardia carcinoma Diseases 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
108060003552 hemocyanin Proteins 0.000 description 3
206010073071 hepatocellular carcinoma Diseases 0.000 description 3
210000003917 human chromosome Anatomy 0.000 description 3
210000004754 hybrid cell Anatomy 0.000 description 3
201000007270 liver cancer Diseases 0.000 description 3
208000014018 liver neoplasm Diseases 0.000 description 3
238000013507 mapping Methods 0.000 description 3
210000001370 mediastinum Anatomy 0.000 description 3
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
238000002156 mixing Methods 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
230000008520 organization Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
-1 polyoxyethylene Polymers 0.000 description 3
238000000746 purification Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
229960004249 sodium acetate Drugs 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
230000017105 transposition Effects 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
210000004291 uterus Anatomy 0.000 description 3
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
208000003200 Adenoma Diseases 0.000 description 2
206010001233 Adenoma benign Diseases 0.000 description 2
101000723867 Arabidopsis thaliana DNA-directed RNA polymerase subunit 10-like protein Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
101000723784 Brassica napus DNA-directed RNA polymerases I, II, and III subunit RPABC5 Proteins 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
206010009269 Cleft palate Diseases 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
208000014311 Cushing syndrome Diseases 0.000 description 2
108010067770 Endopeptidase K Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108091081021 Sense strand Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000000427 antigen Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
230000027455 binding Effects 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
244000309466 calf Species 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000014107 chromosome localization Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
238000009413 insulation Methods 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
210000001630 jejunum Anatomy 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000000867 larynx Anatomy 0.000 description 2
210000000088 lip Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
230000004807 localization Effects 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000000998 lymphohematopoietic effect Effects 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000002969 morbid Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
238000012856 packing Methods 0.000 description 2
206010033675 panniculitis Diseases 0.000 description 2
208000003154 papilloma Diseases 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000012882 sequential analysis Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
230000003595 spectral effect Effects 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
230000004304 visual acuity Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
UZGKAASZIMOAMU-UHFFFAOYSA-N 124177-85-1 Chemical compound NP(=O)=O UZGKAASZIMOAMU-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
AFMZNQYNOSEBLP-YGOYTEALSA-N 5-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-prop-2-ynyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(N)=CN1[C@]1(CC#C)O[C@H](CO)[C@@H](O)C1 AFMZNQYNOSEBLP-YGOYTEALSA-N 0.000 description 1
FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
241000540905 Acnemia Species 0.000 description 1
206010000599 Acromegaly Diseases 0.000 description 1
IMMKUCQIKKXKNP-DCAQKATOSA-N Ala-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CCCN=C(N)N IMMKUCQIKKXKNP-DCAQKATOSA-N 0.000 description 1
OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010001928 Amenorrhoea Diseases 0.000 description 1
206010002027 Amyotrophy Diseases 0.000 description 1
206010002120 Anal atresia Diseases 0.000 description 1
206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 description 1
206010003598 Atelectasis Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
206010004272 Benign hydatidiform mole Diseases 0.000 description 1
208000002880 Bladder exstrophy Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
206010007747 Cataract congenital Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
206010067787 Coagulation factor deficiency Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
206010018325 Congenital glaucomas Diseases 0.000 description 1
206010068321 Congenital inguinal hernia Diseases 0.000 description 1
206010010539 Congenital megacolon Diseases 0.000 description 1
208000016998 Conn syndrome Diseases 0.000 description 1
206010011498 Cryptorchism Diseases 0.000 description 1
UPJGYXRAPJWIHD-CIUDSAMLSA-N Cys-Asn-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UPJGYXRAPJWIHD-CIUDSAMLSA-N 0.000 description 1
HBHMVBGGHDMPBF-GARJFASQSA-N Cys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N HBHMVBGGHDMPBF-GARJFASQSA-N 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
101710112287 DNA-directed RNA polymerases I and III subunit RPAC2 Proteins 0.000 description 1
206010011882 Deafness congenital Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
206010012565 Developmental glaucoma Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
208000027877 Disorders of Sex Development Diseases 0.000 description 1
206010013554 Diverticulum Diseases 0.000 description 1
206010013613 Double ureter Diseases 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
208000007033 Dysgerminoma Diseases 0.000 description 1
201000009051 Embryonal Carcinoma Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
206010053717 Fibrous histiocytoma Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010061159 Foot deformity Diseases 0.000 description 1
206010017577 Gait disturbance Diseases 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
208000007569 Giant Cell Tumors Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
KVBPDJIFRQUQFY-ACZMJKKPSA-N Glu-Cys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O KVBPDJIFRQUQFY-ACZMJKKPSA-N 0.000 description 1
QMOSCLNJVKSHHU-YUMQZZPRSA-N Glu-Met-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O QMOSCLNJVKSHHU-YUMQZZPRSA-N 0.000 description 1
102000051325 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
208000006358 Hand Deformities Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000004592 Hirschsprung disease Diseases 0.000 description 1
KAXZXLSXFWSNNZ-XVYDVKMFSA-N His-Ser-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KAXZXLSXFWSNNZ-XVYDVKMFSA-N 0.000 description 1
101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 1
208000000203 Hyaline Membrane Disease Diseases 0.000 description 1
208000006937 Hydatidiform mole Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000037171 Hypercorticoidism Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
201000002980 Hyperparathyroidism Diseases 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
208000000038 Hypoparathyroidism Diseases 0.000 description 1
KUHFPGIVBOCRMV-MNXVOIDGSA-N Ile-Gln-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N KUHFPGIVBOCRMV-MNXVOIDGSA-N 0.000 description 1
XQLGNKLSPYCRMZ-HJWJTTGWSA-N Ile-Phe-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)O)N XQLGNKLSPYCRMZ-HJWJTTGWSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
208000035478 Interatrial communication Diseases 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
PBCHMHROGNUXMK-DLOVCJGASA-N Leu-Ala-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 PBCHMHROGNUXMK-DLOVCJGASA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
208000019255 Menstrual disease Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 description 1
208000009795 Microphthalmos Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 description 1
XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000008846 Neurocytoma Diseases 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
208000008701 Ovotesticular Disorders of Sex Development Diseases 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
206010070872 Persistent pupillary membrane Diseases 0.000 description 1
INHMISZWLJZQGH-ULQDDVLXSA-N Phe-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 INHMISZWLJZQGH-ULQDDVLXSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
101710183183 Probable DNA-directed RNA polymerases I and III subunit RPAC2 Proteins 0.000 description 1
102100034616 Protein POLR1D, isoform 2 Human genes 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
201000005613 Pseudohermaphroditism Diseases 0.000 description 1
208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
208000006311 Pyoderma Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
101000686018 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) DNA-directed RNA polymerases I, II, and III subunit RPABC1 Proteins 0.000 description 1
101000686026 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) DNA-directed RNA polymerases I, II, and III subunit RPABC2 Proteins 0.000 description 1
101000723834 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) DNA-directed RNA polymerases I, II, and III subunit RPABC3 Proteins 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010043101 Talipes Diseases 0.000 description 1
206010043276 Teratoma Diseases 0.000 description 1
108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 1
KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
206010051320 Thyroglossal cyst Diseases 0.000 description 1
208000026062 Tissue disease Diseases 0.000 description 1
206010044310 Tracheo-oesophageal fistula Diseases 0.000 description 1
208000005864 Tracheoesophageal Fistula Diseases 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
239000006035 Tryptophane Substances 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010046879 Vaginal atresia Diseases 0.000 description 1
BEGDZYNDCNEGJZ-XVKPBYJWSA-N Val-Gly-Gln Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O BEGDZYNDCNEGJZ-XVKPBYJWSA-N 0.000 description 1
URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 1
HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
MJOUSKQHAIARKI-JYJNAYRXSA-N Val-Phe-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 MJOUSKQHAIARKI-JYJNAYRXSA-N 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
210000001943 adrenal medulla Anatomy 0.000 description 1
208000017515 adrenocortical insufficiency Diseases 0.000 description 1
238000005377 adsorption chromatography Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
239000005030 aluminium foil Substances 0.000 description 1
210000001909 alveolar process Anatomy 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
206010002320 anencephaly Diseases 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
208000010133 annular pancreas Diseases 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
208000013914 atrial heart septal defect Diseases 0.000 description 1
206010003664 atrial septal defect Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
201000005271 biliary atresia Diseases 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000011953 bioanalysis Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
239000012295 chemical reaction liquid Substances 0.000 description 1
208000023652 chronic gastritis Diseases 0.000 description 1
230000004087 circulation Effects 0.000 description 1
206010009259 cleft lip Diseases 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
201000000160 cryptorchidism Diseases 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
201000010064 diabetes insipidus Diseases 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
210000002310 elbow joint Anatomy 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
206010016165 failure to thrive Diseases 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000004992 fission Effects 0.000 description 1
239000005357 flat glass Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
201000008361 ganglioneuroma Diseases 0.000 description 1
239000003629 gastrointestinal hormone Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
108010081551 glycylphenylalanine Proteins 0.000 description 1
230000036449 good health Effects 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
208000034737 hemoglobinopathy Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000002758 humerus Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
208000003906 hydrocephalus Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
206010021093 hypospadias Diseases 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
239000000601 hypothalamic hormone Substances 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
230000002989 hypothyroidism Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
208000002358 imperforate anus Diseases 0.000 description 1
230000008676 import Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
208000016274 isolated tracheo-esophageal fistula Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
230000006651 lactation Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
238000010841 mRNA extraction Methods 0.000 description 1
230000036244 malformation Effects 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000013011 mating Effects 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
210000000713 mesentery Anatomy 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000008558 metabolic pathway by substance Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000031864 metaphase Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
201000010478 microphthalmia Diseases 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
239000005445 natural material Substances 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
201000010193 neural tube defect Diseases 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
201000008152 organic acidemia Diseases 0.000 description 1
201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
208000003278 patent ductus arteriosus Diseases 0.000 description 1
239000012071 phase Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
108010064486 phenylalanyl-leucyl-valine Proteins 0.000 description 1
108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000003123 plant toxin Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
208000030761 polycystic kidney disease Diseases 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000012805 post-processing Methods 0.000 description 1
208000013846 primary aldosteronism Diseases 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000009138 pulmonary valve stenosis Diseases 0.000 description 1
208000030390 pulmonic stenosis Diseases 0.000 description 1
238000000197 pyrolysis Methods 0.000 description 1
238000012797 qualification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000003156 radioimmunoprecipitation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
210000000954 sacrococcygeal region Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
208000005893 serous cystadenoma Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
108010048818 seryl-histidine Proteins 0.000 description 1
230000036301 sexual development Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
210000000323 shoulder joint Anatomy 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
229910052714 tellurium Inorganic materials 0.000 description 1
PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
208000013327 true hermaphroditism Diseases 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000003741 urothelium Anatomy 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
201000003130 ventricular septal defect Diseases 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CN 00116959 2000-06-30 2000-06-30 一种新的多肽——人dna依赖的rna多聚酶ac40亚单位抑制物9.13和编码这种多肽的多核苷酸 Pending CN1331299A (zh)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
CN 00116959 CN1331299A (zh)	2000-06-30	2000-06-30	一种新的多肽——人dna依赖的rna多聚酶ac40亚单位抑制物9.13和编码这种多肽的多核苷酸
AU2002210323A AU2002210323A1 (en)	2000-06-30	2001-06-29	A novel polypeptide-human dna-dependent rna polymerase ac40 subunit inhibitor 9.13 and the polynucleotide encoding said polypeptide
PCT/CN2001/001084 WO2002026969A1 (fr)	2000-06-30	2001-06-29	Nouveau polypeptide, inhibiteur humain 9.13 de la sous-unite ac40 d'arn-polymerase adn-dependante, et polynucleotide codant ce polypeptide

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN 00116959 CN1331299A (zh)	2000-06-30	2000-06-30	一种新的多肽——人dna依赖的rna多聚酶ac40亚单位抑制物9.13和编码这种多肽的多核苷酸

Publications (1)

Publication Number	Publication Date
CN1331299A true CN1331299A (zh)	2002-01-16

Family

ID=4586358

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN 00116959 Pending CN1331299A (zh)	2000-06-30	2000-06-30	一种新的多肽——人dna依赖的rna多聚酶ac40亚单位抑制物9.13和编码这种多肽的多核苷酸

Country Status (3)

Country	Link
CN (1)	CN1331299A (fr)
AU (1)	AU2002210323A1 (fr)
WO (1)	WO2002026969A1 (fr)

2000
- 2000-06-30 CN CN 00116959 patent/CN1331299A/zh active Pending
2001
- 2001-06-29 AU AU2002210323A patent/AU2002210323A1/en not_active Abandoned
- 2001-06-29 WO PCT/CN2001/001084 patent/WO2002026969A1/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2002026969A1 (fr)	2002-04-04
AU2002210323A1 (en)	2002-04-08

Publication	Publication Date	Title
CN1331340A (zh)	2002-01-16	一种新的多肽——人拓扑异构酶12.1和编码这种多肽的多核苷酸
CN1331213A (zh)	2002-01-16	一种新的多肽——人大蛋白10.01和编码这种多肽的多核苷酸
CN1328053A (zh)	2001-12-26	一种新的多肽——人ftsH蛋白16.83和编码这种多肽的多核苷酸
CN1333274A (zh)	2002-01-30	一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸
CN1340520A (zh)	2002-03-20	一种新的多肽——多聚腺苷酸结合蛋白33.11和编码这种多肽的多核苷酸
CN1352194A (zh)	2002-06-05	一种新的多肽——人亮氨酸拉链蛋白10.01 和编码这种多肽的多核苷酸
CN1338468A (zh)	2002-03-06	一种新的多肽——人芳香烃受体蛋白15.73和编码这种多肽的多核苷酸
CN1339449A (zh)	2002-03-13	一种新的多肽——70KD U1－snRNP剪接因子相关蛋白58.74和编码这种多肽的多核苷酸
CN1331299A (zh)	2002-01-16	一种新的多肽——人dna依赖的rna多聚酶ac40亚单位抑制物9.13和编码这种多肽的多核苷酸
CN1328036A (zh)	2001-12-26	一种新的多肽——人p300/CBP结合因子10.56和编码这种多肽的多核苷酸
CN1331199A (zh)	2002-01-16	一种新的多肽——人转录生长调控因子β激活蛋白14.08和编码这种多肽的多核苷酸
CN1331211A (zh)	2002-01-16	一种新的多肽——人核蛋白10.45和编码这种多肽的多核苷酸
CN1339490A (zh)	2002-03-13	一种新的多肽——人大蛋白055120.24和编码这种多肽的多核苷酸
CN1329087A (zh)	2002-01-02	一种新的多肽——人锌指蛋白13.64和编码这种多肽的多核苷酸
CN1329085A (zh)	2002-01-02	一种新的多肽——人锌指蛋白15.29和编码这种多肽的多核苷酸
CN1331231A (zh)	2002-01-16	一种新的多肽——人大蛋白10.12和编码这种多肽的多核苷酸
CN1333261A (zh)	2002-01-30	一种新的多肽——人大蛋白10.23和编码这种多肽的多核苷酸
CN1364805A (zh)	2002-08-21	一种新的多肽——人细胞的分裂与增殖调控蛋白11.88和编码这种多肽的多核苷酸
CN1331210A (zh)	2002-01-16	一种新的多肽——人酸性纤维原细胞生长因子结合因子10.78和编码这种多肽的多核苷酸
CN1340624A (zh)	2002-03-20	一种新的多肽——人组织蛋白酶10.12和编码这种多肽的多核苷酸
CN1331163A (zh)	2002-01-16	一种新的多肽——人转录调控因子zfm1异构体19.47和编码这种多肽的多核苷酸
CN1340526A (zh)	2002-03-20	一种新的多肽——蛋白酶体hc2亚基64.57和编码这种多肽的多核苷酸
CN1329030A (zh)	2002-01-02	一种新的多肽——人mrl3蛋白11.55和编码这种多肽的多核苷酸
CN1339460A (zh)	2002-03-13	一种新的多肽——人切割刺激因子50Kd a亚基86.35和编码这种多肽的多核苷酸
CN1339603A (zh)	2002-03-13	一种新的多肽——人26s蛋白酶体调节亚单位64.35和编码这种多肽的多核苷酸

Legal Events

Date	Code	Title
2002-01-16	C06	Publication
2002-01-16	PB01	Publication
2004-04-28	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2004-04-28	WD01	Invention patent application deemed withdrawn after publication